Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 31, Number 6—June 2025

Research

Long-Term Clinical Outcomes of Adults Hospitalized for COVID-19 Pneumonia

Ivan O. RosasComments to Author , Alejandra Benitez, James A. McKinnell, Reena Shah, Michael Waters, Bradley D. Hunter, Robert Jeanfreau, Larry Tsai, Margaret Neighbors, Ben Trzaskoma, Rita de Cassia Castro, and Fang Cai
Author affiliation: Baylor College of Medicine, Houston, Texas, USA (I.O. Rosas); Genentech, South San Francisco, California, USA (A. Benitez, L. Tsai, M. Neighbors, B. Trzaskoma, R. de Cassia Castro, F. Cai); Torrance Memorial Medical Center, Torrance, California, USA (J.A. McKinnell); Aga Khan University Hospital, Nairobi, Kenya (R. Shah); Velocity Clinical Research, Chula Vista, California, USA (M. Waters); Intermountain Healthcare, Salt Lake City, Utah, USA (B.D. Hunter); Velocity Clinical Research, New Orleans, Louisiana, USA (R. Jeanfreau)

Main Article

Figure 2

Disposition of LOPAC study participants in study of long-term clinical outcomes of adults hospitalized for COVID-19 pneumonia. The parent studies were clinical trials (registered with https://www.clinicaltrials.gov) as follows: EMPACTA (study no. NCT04372186), COVACTA (no. NCT04320615), MARIPOSA (no. NCT04363736), COVASTIL (no. NCT04386616), and REMDACTA (no. NCT04409262). Participants might have received remdesivir or another antiviral drug as part of the standard of care in the EMPACTA, COVACTA, and MARIPOSA studies. Participants who were randomly assigned to receive placebo, astegolimab, or efmarodocokin alfa might have also received TCZ or remdesivir or both as part of the standard of care in the COVASTIL study. Participants randomly assigned to receive TCZ or placebo in the REMDACTA study also received remdesivir. *Number of participants in each parent study; †number of participants from each parent study who participated in the LOPAC study; ‡1 participant initially enrolled in the LOPAC study did not receive treatment in the parent study and was not included in any analyses for the parent or LOPAC study. LOPAC, Long-Term Outcomes Post Acute COVID-19 study; TCZ, tocilizumab.

Figure 2. Disposition of LOPAC study participants in study of long-term clinical outcomes of adults hospitalized for COVID-19 pneumonia. The parent studies were clinical trials (registered with https://www.clinicaltrials.gov) as follows: EMPACTA (study no. NCT04372186), COVACTA (no. NCT04320615), MARIPOSA (no. NCT04363736), COVASTIL (no. NCT04386616), and REMDACTA (no. NCT04409262). Participants might have received remdesivir or another antiviral drug as part of the standard of care in the EMPACTA, COVACTA, and MARIPOSA studies. Participants who were randomly assigned to receive placebo, astegolimab, or efmarodocokin alfa might have also received TCZ or remdesivir or both as part of the standard of care in the COVASTIL study. Participants randomly assigned to receive TCZ or placebo in the REMDACTA study also received remdesivir. *Number of participants in each parent study; †number of participants from each parent study who participated in the LOPAC study; ‡1 participant initially enrolled in the LOPAC study did not receive treatment in the parent study and was not included in any analyses for the parent or LOPAC study. LOPAC, Long-Term Outcomes Post Acute COVID-19 study; TCZ, tocilizumab.

Main Article

Page created: March 24, 2025
Page updated: May 20, 2025
Page reviewed: May 20, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external